These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24451612)

  • 21. WHO/ISH total risk approach for primary prevention of cardiovascular disease shows greater decrease in costs for women but not the elderly in Jamaica.
    Abdulkadri AO; Tulloch-Reid MK; Francis DK; Gordon-Strachan GM; Younger-Coleman NO; Rocke KD; McFarlane SR; Cunningham-Myrie CA; Ferguson TS; Wilks RJ; Anderson SG
    J Clin Epidemiol; 2015 Sep; 68(9):994-1001. PubMed ID: 25819490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health and Economic Impacts of the National Menu Calorie Labeling Law in the United States: A Microsimulation Study.
    Liu J; Mozaffarian D; Sy S; Lee Y; Wilde PE; Abrahams-Gessel S; Gaziano T; Micha R;
    Circ Cardiovasc Qual Outcomes; 2020 Jun; 13(6):e006313. PubMed ID: 32493057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of financial incentives and disincentives for improving food purchases and health through the US Supplemental Nutrition Assistance Program (SNAP): A microsimulation study.
    Mozaffarian D; Liu J; Sy S; Huang Y; Rehm C; Lee Y; Wilde P; Abrahams-Gessel S; de Souza Veiga Jardim T; Gaziano T; Micha R
    PLoS Med; 2018 Oct; 15(10):e1002661. PubMed ID: 30278053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang.
    Wei X; Zou G; Gong W; Yin J; Yu Y; Walley J; Zhang Z; King R; Chen K; Chong MK; Zee BC; Liu S; Tang J; Griffiths S; Yu M
    Trials; 2013 Oct; 14():354. PubMed ID: 24160442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling.
    Perera R; McFadden E; McLellan J; Lung T; Clarke P; Pérez T; Fanshawe T; Dalton A; Farmer A; Glasziou P; Takahashi O; Stevens J; Irwig L; Hirst J; Stevens S; Leslie A; Ohde S; Deshpande G; Urayama K; Shine B; Stevens R
    Health Technol Assess; 2015 Dec; 19(100):1-401, vii-viii. PubMed ID: 26680162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study.
    Vedanthan R; Kamano JH; Lee H; Andama B; Bloomfield GS; DeLong AK; Edelman D; Finkelstein EA; Hogan JW; Horowitz CR; Manyara S; Menya D; Naanyu V; Pastakia SD; Valente TW; Wanyonyi CC; Fuster V
    Am Heart J; 2017 Jun; 188():175-185. PubMed ID: 28577673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does Targeting Higher Health Risk Employees or Increasing Intervention Intensity Yield Savings in a Workplace Wellness Program?
    Kapinos KA; Caloyeras JP; Liu H; Mattke S
    J Occup Environ Med; 2015 Dec; 57(12):1257-61. PubMed ID: 26641821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974.
    Cooley K; Szczurko O; Perri D; Mills EJ; Bernhardt B; Zhou Q; Seely D
    PLoS One; 2009 Aug; 4(8):e6628. PubMed ID: 19718255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD; Gillett M; Holmes M; Ogden E
    Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years.
    Robertson W; Fleming J; Kamal A; Hamborg T; Khan KA; Griffiths F; Stewart-Brown S; Stallard N; Petrou S; Simkiss D; Harrison E; Kim SW; Thorogood M
    Health Technol Assess; 2017 Jan; 21(1):1-180. PubMed ID: 28059054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of osteopathy in primary care: results from a pragmatic randomized controlled trial.
    Williams NH; Edwards RT; Linck P; Muntz R; Hibbs R; Wilkinson C; Russell I; Russell D; Hounsome B
    Fam Pract; 2004 Dec; 21(6):643-50. PubMed ID: 15531626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costs, benefits and effectiveness of worksite physical activity counseling from the employer's perspective.
    Proper KI; de Bruyne MC; Hildebrandt VH; van der Beek AJ; Meerding WJ; van Mechelen W
    Scand J Work Environ Health; 2004 Feb; 30(1):36-46. PubMed ID: 15018027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
    Lewis B; Watts GF; Sullivan DR
    Heart Lung Circ; 2010 Apr; 19(4):225-7. PubMed ID: 20149730
    [No Abstract]   [Full Text] [Related]  

  • 37. An economic evaluation of four work site based cardiovascular risk factor interventions.
    Oldenburg B; Owen N; Parle M; Gomel M
    Health Educ Q; 1995 Feb; 22(1):9-19. PubMed ID: 7721604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
    Dehmer SP; Maciosek MV; LaFrance AB; Flottemesch TJ
    Ann Fam Med; 2017 Jan; 15(1):23-36. PubMed ID: 28376458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
    Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
    Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial.
    Luymes CH; Poortvliet RKE; van Geloven N; de Waal MWM; Drewes YM; Blom JW; Smidt N; Assendelft WJJ; van den Hout WB; de Ruijter W; Numans ME
    BMC Med; 2018 Jan; 16(1):5. PubMed ID: 29321031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.